We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 05, 2022

Effect of Dapagliflozin Across the Range of LVEF in Patients With Heart Failure

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Nat. Med. 2022 Aug 27;[EPub Ahead of Print], PS Jhund, T Kondo, JH Butt, KF Docherty, BL Claggett, AS Desai, M Vaduganathan, SB Gasparyan, O Bengtsson, D Lindholm, M Petersson, AM Langkilde, RA de Boer, D DeMets, AF Hernandez, SE Inzucchi, MN Kosiborod, L Køber, CSP Lam, FA Martinez, MS Sabatine, SJ Shah, SD Solomon, JJV McMurray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading